Advertisement

The effect of l-carnitine on plasma lipoprotein(a) levels in hypercholesterolemic patients with type 2 diabetes mellitus

      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      Background: A previous study has demonstrated that l-carnitine reduces plasma lipoprotein(a) (Lp[a]) levels in patients with hypercholesterolemia.
      Objective: To test a tolerable Lp(a)-reducing agent in diabetic patients, we assessed the effect of a dietary supplementation of l-carnitine on plasma lipid levels, particularly Lp(a), of patients with type 2 diabetes mellitus (DM) and hypercholesterolemia.
      Methods: In this 6-month, randomized, double-masked, placebo-controlled clinical trial, patients were enrolled, assessed, and followed up at the Diabetic and Metabolic Diseases Center of the Department of Internal Medicine and Therapeutics at the University of Pavia, Pavia, Italy. All study patients had newly diagnosed type 2 DM that was managed through dietary restriction alone throughout the study, as well as hypercholesterolemia. Patients were randomized to 1 of 2 groups. One group received l-carnitine, one 1-g tablet BID. The other group received a corresponding placebo. We assessed body mass index, fasting plasma glucose, postprandial plasma glucose, glycosylated hemoglobin, fasting plasma insulin, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein (apo) A-I, apo B, and Lp(a) at baseline and at 1, 3, and 6 months of treatment.
      Results: This study included 94 patients. The treatment group included 24 men and 22 women (mean [SD] age, 52 [6] years). The placebo group included 23 men and 25 women (mean [SD] age, 50 [7] years). The baseline characteristics of the groups did not differ significantly. The mean (SD) body weight, height, and body mass index were 78.2 (5.8) kg, 1.70 (0.04) m, and 27.3 (2.5) kg/m2, respectively, in the l-carnitine group and 77.6 (6.4) kg, 1.71 (0.05) m, and 26.8 (2.2) kg/m2, respectively, in the placebo group. In the treatment group, Lp(a) was significantly reduced at 3 and 6 months compared with baseline (P < 0.05) and P < 0.01, respectively). We observed a significant improvement after 6 months (P < 0.05) in the Lp(a) value in patients taking l-carnitine compared with those taking placebo. Between-group differences in other variables did not reach a level of significance at months 3 and 6. No drug-related adverse events were reported or observed.
      Conclusion: In this preliminary study, after 3 and 6 months, l-carnitine significantly lowered the plasma Lp(a) level compared with placebo in selected hypercholesterolemic patients with newly diagnosed type 2 DM.

      Keywords

      To read this article in full you will need to make a payment
      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. JAMA. 2001; 285: 2486-2497
        • Marcovina S.M.
        • Koschinsky M.L.
        Lipoprotein(a) as a risk factor for coronary artery disease.
        Am J Cardiol. 1998; 82: 57-66
        • Glader C.A.
        • Birgander L.S.
        • Stenlund H.
        • Dahlen G.H.
        Is lipoprotein(a) a predictor for survival in patients with established coronary artery disease? Results from a prospective patient cohort study in northern Sweden.
        J Intern Med. 2002; 252: 27-35
        • Peltier M.
        • Iannetta Peltier M.C.
        • Sarano M.E.
        • et al.
        Elevated serum lipoprotein(a) level is an independent marker of severity of thoracic aortic atherosclerosis.
        Chest. 2002; 1212: 1589-1594
        • Misirli H.
        • Somay G.
        • Ozbal N.
        • Yasar Erenoglu N.
        Relation of lipid and lipoprotein(a) to ischaemic stroke.
        J Clin Neurosci. 2002; 9: 127-132
        • Nawawi H.M.
        • Muhajir M.
        • Kian Y.C.
        • et al.
        Type of diabetes and waist-hip ratio are important determinants of serum lipoprotein(a) levels in diabetic patients.
        Diabetes Res Clin Pract. 2002; 56: 221-227
        • Maca T.H.
        • Ahmadi R.
        • Derfler K.
        • et al.
        Influence of lipoprotein(a) on restenosis after femoropopliteal percutaneous transluminal angioplasty in Type 2 diabetic patients.
        Diabet Med. 2002; 19: 300-306
        • Tarkun I.
        • Cetinarslan B.
        • Canturk Z.
        Lipoprotein(a) concentrations in patients with type 2 diabetes mellitus without cardiovascular disease: Relationship to metabolic parameters and diabetic complications.
        Nutr Metab Cardiovasc Dis. 2002; 12: 127-131
        • Akaike M.
        • Azuma H.
        • Kagawa A.
        • et al.
        Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases.
        Clin Chem. 2002; 48: 1454-1459
        • Soma M.R.
        • Osnago-Gadda I.
        • Paoletti R.
        • et al.
        The lowering of lipoprotein(a) induced by estrogen plus progesterone replacement therapy in postmenopausal women.
        Arch Intern Med. 1993; 153: 1462-1468
        • Sirtori C.R.
        • Calabresi L.
        • Ferrara S.
        • et al.
        l-carnitine reduces plasma lipoprotein(a) levels in patients with hyper Lp(a).
        Nutr Metab Cardiovasc Dis. 2000; 10: 247-251
        • Pan J.
        • Van J.T.
        • Chan E.
        • et al.
        Extended-release niacin treatment of the atherogenic lipid profile and lipoprotein(a) in diabetes.
        Metabolism. 2002; 51: 1120-1127
        • American Diabetes Association
        Screening for Diabetes (Position Statement).
        Diabetes Care. 2001; 24: S21-S24
      2. Proposed International Guidelines for Biomedical Research Involving Human Subjects. The Council for International Organisation of Medical Sciences, Geneva1982
      3. Diabet Med. 1999; 16: 716-730
        • Heding L.G.
        Determination of total serum insulin (IRI) in insulin-treated diabetic patients.
        Diabetologia. 1972; 8: 260-266
        • Bunn H.F.
        • Gabbay K.H.
        • Gallop P.M.
        The glycosylation of hemoglobin: Relevance to diabetes mellitus.
        Science. 1978; 200: 21-27
        • Klose S.
        • Borner K.
        Enzymatic determination of total cholesterol with the Greiner Selective Analyzer (GSA II).
        J Clin Chem Clin Biochem. 1977; 15 ([in German]): 121-130
        • Wahlefeld A.W.
        Triglycerides determination after enzymatic hydrolysis.
        in: Bermeyer H.U. Methods of Enzymatic Analysis. 2nd English ed. Academic Press, New York1974: 18-31
        • Havel R.J.
        • Eder H.A.
        • Bragdon J.H.
        The distribution and chemical composition of ultra-centrifugally separated lipoproteins in human serum.
        J Clin Invest. 1955; 34: 1345-1353
        • Friedewald W.T.
        • Levy R.I.
        • Fredrickson D.S.
        Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.
        Clin Chem. 1972; 18: 499-502
        • Leblond L.
        • Marcel Y.L.
        The amphipathic alpha-helical repeats of apolipoprotein A-I are responsible for binding of high density lipoproteins to HepG2 cells.
        J Biol Chem. 1991; 266: 6058-6067
        • De Loof H.
        • Rosseneu M.
        • Yang C.Y.
        • et al.
        Human apolipoprotein B: Analysis of internal repeatsand homology with other apolipoproteins.
        J Lipid Res. 1987; 28: 1455-1465
        • Scanu A.M.
        • Scandiani L.
        Lipoprotein(a): Structure, biology, and clinical relevance.
        Adv Intern Med. 1991; 36: 249-270
        • Utermann G.
        • Menzel H.J.
        • Kraft H.G.
        • et al.
        Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentration in plasma.
        J Clin Invest. 1987; 80: 458-465
        • Diaz M.
        • Lopez F.
        • Hernandez F.
        • Urbina J.A.
        l-carnitine effects on chemical composition of plasma lipoproteins of rabbits fed with normal and high cholesterol diets.
        Lipids. 2000; 35: 627-632
        • Golper T.A.
        • Wolfson M.
        • Ahmad S.
        • et al.
        Multicenter trial of l-carnitine in maintenance hemodialysis patients. I. Carnitine concentrations and lipid effects.
        Kidney Int. 1990; 38: 904-911
        • Maebashi M.
        • Kawamura N.
        • Sato M.
        • et al.
        Lipid-lowering effect of carnitine in patients with type-IV hyperlipoproteinaemia.
        Lancet. 1978; 2: 805-807
        • Elisaf M.
        • Bairaktari E.
        • Katopodis K.
        • et al.
        Effect of l-carnitine supplementation on lipid parameters in hemodialysis patients.
        Am J Nephrol. 1998; 18: 416-421
        • Vesela E.
        • Racek J.
        • Trefil L.
        • et al.
        Effect of l-carnitine supplementation in hemodialysis patients.
        Nephron. 2001; 88: 218-223
        • Gaw A.
        • Hobbs H.H.
        Molecular genetics of lipoprotein(a): New pieces to the puzzle.
        Curr Opin Lipidol. 1994; 5: 149-155
        • Zysow B.R.
        • Kauser K.
        • Lawn R.M.
        • Rubanyi G.M.
        Effects of estrus cycle, ovariectomy, and treatment with estrogen, tamoxifen, and progesterone on apolipoprotein(a) gene expression in transgenic mice.
        Arterioscler Thromb Vasc Biol. 1997; 17: 1741-1745
        • Carlson L.A.
        • Hamsten A.
        • Asplund A.
        Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid.
        J Intern Med. 1989; 226: 271-276
        • Ramharack R.
        • Spahr M.A.
        • Sekerke C.S.
        • et al.
        CI-1011 lowers lipoprotein(a) and plasma cholesterol concentrations in chow-fed cynomolgus monkeys.
        Atherosclerosis. 1998; 136: 79-87
        • Tamamogullari N.
        • Silig Y.
        • Icagasioglu S.
        • Atalay A.
        Carnitine deficiency in diabetes mellitus complications.
        J Diabetes Complications. 1999; 13: 251-253
        • Malone J.I.
        • Schocken D.D.
        • Morrison A.D.
        • Gilbert-Barness E.
        Diabetic cardiomyopathy and carnitine deficiency.
        J Diabetes Complications. 1999; 13: 86-90
        • Digiesi V.
        • Cantini F.
        • Bisi G.
        • et al.
        l-carnitine adjuvant therapy in essential hypertension.
        Clin Ther. 1994; 144: 391-395